AC Immune Stock Forecast, Price & News

+0.17 (+2.39 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume294,598 shs
Average Volume219,536 shs
Market Capitalization$528.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

AC Immune logo

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

918th out of 2,216 stocks

Pharmaceutical Preparations Industry

442nd out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

Is AC Immune a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AC Immune stock.
View analyst ratings for AC Immune
or view top-rated stocks.

What stocks does MarketBeat like better than AC Immune?

Wall Street analysts have given AC Immune a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AC Immune wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AC Immune?

AC Immune saw a increase in short interest in June. As of June 15th, there was short interest totaling 1,290,000 shares, an increase of 25.2% from the May 31st total of 1,030,000 shares. Based on an average daily trading volume, of 472,600 shares, the days-to-cover ratio is currently 2.7 days. Approximately 3.3% of the company's stock are short sold.
View AC Immune's Short Interest

When is AC Immune's next earnings date?

AC Immune is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for AC Immune

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings results on Wednesday, November, 18th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.01. The firm had revenue of $1.22 million for the quarter, compared to the consensus estimate of $0.93 million. AC Immune had a negative trailing twelve-month return on equity of 31.66% and a negative net margin of 405.01%.
View AC Immune's earnings history

How has AC Immune's stock been impacted by Coronavirus (COVID-19)?

AC Immune's stock was trading at $5.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACIU stock has increased by 32.6% and is now trading at $7.28.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ACIU?

1 equities research analysts have issued 1-year price targets for AC Immune's shares. Their forecasts range from $16.00 to $16.00. On average, they anticipate AC Immune's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 119.8% from the stock's current price.
View analysts' price targets for AC Immune
or view top-rated stocks among Wall Street analysts.

Who are AC Immune's key executives?

AC Immune's management team includes the following people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 64, Pay $1.14M)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 43)
  • Mr. Piergiorgio Donati, Chief Technical Operations Officer (Age 50)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 63)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 50)
  • Joshua Drumm Ph.D., Head of Investor Relations
  • Mr. Alexandre Caratsch, Gen. Counsel (Age 55)
  • Judith Moore, Global Head of Communications
  • Mr. Gautam Maitra Fil. Lic, Head of Regulatory & External Affairs and Sr. Expert
  • Dr. Maria Pihlgren Ph.D., Head of Biology

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune CEO Andrea Pfeifer on Andrea Pfeifer has an approval rating of 35% among AC Immune's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AC Immune's key competitors?

What other stocks do shareholders of AC Immune own?

When did AC Immune IPO?

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different institutional and retail investors. Top institutional shareholders include Compagnie Lombard Odier SCmA (0.02%).

Which institutional investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $7.28.

How much money does AC Immune make?

AC Immune has a market capitalization of $528.89 million and generates $16.46 million in revenue each year. The company earns $-66,040,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does AC Immune have?

AC Immune employs 125 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is

Where are AC Immune's headquarters?

AC Immune is headquartered at EPFL Innovation Park Building B, Lausanne V8, 1015.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.